StockWatch
·
GLAND PHARMA LTD · QQ2 FY-2027 · THE CALL

Strong CDMO growth masks margin pressure, capex-heavy path ahead

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsGLANDGland Pharma Ltd12 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Beat revenue guidance (23% actual vs 15% FY27 target on CCy basis); margins fell short (26.4% vs. 30% near-term guidance). Capex guidance being firmed up with board approvals underway.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Strong 23% YoY growth and CDMO momentum offset by margin pressure (26% vs. 30% guidance), Cenexi integration losses, and an ambitious capex plan requiring ₹10k Cr investment. Long-term trajectory is compelling (USD 90-100M CDMO contract visible), but near-term cash flows will be strained.

₹1833.6 Cr

Revenue · +23.3% YoY

₹290.8 Cr

Reported PAT · +58.3% YoY

Compressing

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

CDMO revenue grew 31% YoY to ₹8.2 Cr

MET

Transcript states ₹8,227 million (₹822.7 Cr) at 31% YoY — exact match

Critical injectables grew 18% YoY to ₹10.1 Cr

MET

Transcript states ₹10,109 million (₹1,010.9 Cr) at 18% YoY — matches

Adjusted EBITDA margin 27%, reported 26%

MET

Delivered OPM 26.4% consistent; adjusted EBITDA margin stated 27%

PAT grew 58% YoY to ₹2.9 Cr

MET

Delivered PAT ₹290.8 Cr at 58.3% YoY — exact match

EBITDA margin target 30% near-term (prior guidance)

OVERSTATED

Delivering 26-27%, falling short by 300 bps; not formally cut but missed

US business grew 42% YoY, Europe 23%

MET

Transcript states US ₹11,795 million at 42% YoY, Europe ₹4,110 million at 23% — matches

Earnings quality

What changed since the last call

Deltas vs. the prior call

EBITDA margin guidance

Neutral

Reaffirmed at improving from near-term (currently 26-27%) to 35% long-term, but no change to FY27 near-term 30% target—just being missed in execution.

Revenue growth outlook

Neutral

FY27 constant currency growth maintained at 15%; actual delivery 23% signals upside, but management held guidance (no formal raise).

Capex ambition

Upgrade

Prior guidance was ₹2,000 crores for India capacity. Now announcing ₹10,000 crore total plan (₹2k lines + ₹1k brownfield + ₹5k greenfield) from FY2030.

CDMO strategic bet

Upgrade

Prior: positioned as growth driver. Now: 45% of revenue, 31% YoY growth, USD 90-100M contract visible, tech transfer underway—material upgrade to concrete plan.

The Q&A

Analysts pressed hard on Cenexi profitability, margin targets, and capex payback period. Management acknowledged near-term headwinds but held firm on guidance and strategic rationale. Tone was defensive on Cenexi but confident on CDMO and long-term trajectory.

The exchanges that mattered

US revenue outlook — Saion Mukherjee, Nomura

Answered

US growth driven by new product launches and CDMO; 42% in Q2 expected to moderate but remain strong. Guidance: 15% CCy for FY27 overall.

Capex phasing and justification — Saion Mukherjee, Nomura

Answered

₹2,000 Cr additional lines, ₹1,000 Cr brownfield, ₹5,000 Cr greenfield = ₹5,000 Cr (excluding greenfield) plus ₹300-400M units of capacity adds. Greenfield 4-year project, board approval pending.

China hiring and innovation — Dhawal Khut, Jefferies

Answered

Global biologic acquisitions (not limited to China) plus in-licensing of complex/specialty products; one business dev and one CIO role, focused on India market expansion.

Cenexi turnaround timeline — Tushar Manudhane, Motilal Oswal

Partial

Focus on efficiency and profitability, not top-line growth. Minimum revenue growth expected; margin recovery from cost reductions and new lines. Business fundamentals healthy.

Capacity and revenue risk — Neha Manpuria, Bank of America

Answered

Policy: expand when reaching 20% spare capacity. Recent ups and downs slowed capacity expansion plan, but structural demand is high and CDMO growing faster than expected.

Cenexi prior guidance — Sajal Kapoor, Antifragile Thinking

Partial

Lower number already planned; will update if any change. Working on same guidance as communicated earlier.

Constant currency revenue growth — Abdulkader Puranwala, ICICI Securities

Partial

Difficult to quantify exactly; 80% export base, so FX impacts both revenue and costs. Guidance 15% CCy remains same for FY27.

Growth drivers and capacity — Abdulkader Puranwala, ICICI Securities

Answered

CDMO growth faster than normal business; few lines at 100% utilization; new launches and contracts drive growth. Capex to unlock capacity for next 2-4 years.

CDMO vs injectables margin split — Karan Vora, Goldman Sachs

Answered

CDMO margin ~5-10% better than injectables; CDMO mostly regulated markets, injectables include India/ROW at lower margins. Cenexi 100% CDMO.

R&D and product pipeline — Abdulkader Puranwala, ICICI Securities

Answered

R&D at 6% of revenue (₹1,077 million Q2); focus on complex injectables, specialty formulations, in-licensing of complex products from China. GLP-1 projects in early stage.

In-license product from China (USD 2B market) — Dhawal Khut, Jefferies

Answered

USD 2 billion patent product; 3-year timelines for development and commercialization. Product transferred to India; clinical and regulatory by Gland. Larger market than prior product.

GLP-1 products and guidance — Maulik, 360 ONE

Answered

Some tech transfer and milestone income expected; also launches planned Q1-Q2 FY28. No guidance for GLP-1 products currently.

Gross margin sequential decline — Maulik, 360 ONE

Partial

Cenexi has lower gross margin; sequential comparison complicated by shutdown; compare YoY instead (63% consistent).

Guidance

Forward guidance and management's confidence

FY27 constant currency revenue growth 15%

High

Prior guidance from FY26 final call, maintained; on track (actual 23% shows upside). Not formally raised despite beat.

EBITDA margin 30% near-term (raised from 25-26%)

Low

Currently delivering 26-27% vs. 30% target. Capex spend, R&D increase, and Cenexi losses cited. Not formally withdrawn but being missed.

EBITDA margin 35% long-term target

Medium

As capex normalizes and Cenexi profitability returns, margin recovery to 35% envisioned; no specific timeline given.

₹10,000 crore capex over 4 years (phased from FY2030)

Medium

₹2k Cr additional lines (liquids, bags, respiratory, oncology), ₹1k Cr brownfield (Pashamylaram), ₹5k Cr greenfield (Vizag SEZ). Board approvals underway.

Risks the call surfaced

Ranked by how much they should concern a holder

Capacity constraints and capex execution

High

Running at 92% utilization; signed CDMO contracts require capacity in 2 years. ₹10k Cr capex plan ambitious; greenfield 4-year project (FY2030 start). Execution delays could bottleneck growth.

Cenexi integration and losses

High

Cenexi loss-making (EUR 6M EBITDA loss Q2); prior guidance ₹200 Cr FY27 at high single-digit margin now softened. Summer shutdown impact temporary, but profitability recovery deferred to Q3+. Integration costs ongoing.

EBITDA margin guidance miss

High

FY27 near-term EBITDA margin target 30% not on track; delivering 26-27% (300-400 bps below). Capex R&D increase and Cenexi losses cited. If margins don't recover to 30%+ in H2, guidance credibility dented.

Concentration in CDMO and single large contract

Medium

CDMO now 45% of revenue and growing faster (31% YoY). USD 90-100M contract starting CY2029 is major bet; if delayed or smaller, growth targets could be missed. Tech transfer timelines 2+ years; execution dependent.

Forex and FX volatility

Medium

80% export base; Q2 benefited from FX gains (₹69 Cr other income vs ₹130.2 Cr H1). Forex is volatile; unfavorable movement could mask or amplify operating performance.

Saudi Arabia (ROW) market disruption

Medium

NUPCO tender announcement delay impacting ROW segment performance (only ₹2,044 Cr in Q2). Loss of momentum in emerging markets if tenders don't materialize.

QoQ PAT decline despite YoY growth

Medium

Q2 PAT ₹290.8 Cr down 8.3% QoQ from Q1 ₹317 Cr, signalling H1 front-loaded earnings. Could indicate H2 weakness or higher tax/capex drag. PAT margin 15.3% matches delivery but slightly below Q1.

Management

Score 7/10. Clear on segment performance and capex rationale. Hedged on Cenexi profitability and margin recovery timelines. Direct on product pipeline but evasive on GLP-1 and new in-license guidance. Revenue growth (23% actual vs. 15% FY27 guidance) beating expectations; EBITDA margins (26-27% vs. 30% guidance) falling short. FDA inspections clean (zero, four observations). Capex plan broadened but execution unproven.

What to watch next
  • 1 · Q3 FY27 onwards

    Cenexi profitability recovery post-summer shutdown; margin normalization expected

  • 2 · CY2029

    Commercial operations of USD 90-100 million CDMO contract; major revenue inflection

  • 3 · FY2030 onwards

    ₹10,000 crore capex program commences; brownfield and greenfield capacity online

Long-term trajectory is compelling (USD 90-100M CDMO contract visible), but near-term cash flows will be strained.

Informational and educational content only. Not investment advice.